{"links":{"html":"https://www.erudio.com/reports/heron-lung01-nct06671379","json":"https://www.erudio.com/reports/heron-lung01-nct06671379.json","markdown":"https://www.erudio.com/reports/heron-lung01-nct06671379.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"heron-lung01-06671379"}},"request":"https://www.erudio.com/contact?report=heron-lung01-06671379"},"offer":{"cited_commentary_sources":10,"verified_hcp_statements":30,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":8,"optional":true,"price_per_verified_person_usd":15,"price_usd":120,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"heron-lung01-nct06671379"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=heron-lung01-06671379","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/heron-lung01-nct06671379","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T07:40:20.185513Z","notify_subscribers":false,"status":"corrected","summary":"Corrected to match the delivered report: 12 sources cited (was 10); source breakdowns; the sample findings."},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":7,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":7,"title":"Primary endpoint: Progression-free survival (PFS) assessed by BICR according to RECIST v1.1"},{"claim_count":6,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":6,"title":"Secondary endpoints"},{"claim_count":5,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":6,"title":"The comparison"},{"claim_count":7,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":6,"title":"Safety and tolerability"},{"claim_count":6,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":3,"coverage":"discussed","id":"A1","source_count":2,"title":"Readiness for standard-of-care adoption"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":3,"title":"Predictive selection and resistance-directed testing"},{"claim_count":6,"coverage":"discussed","id":"A3","source_count":4,"title":"Competing options, combinations and treatment sequence"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":2,"title":"Applicability outside China"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"Intracranial activity and brain-metastasis evaluation"},{"claim_count":5,"coverage":"discussed","id":"A6","source_count":3,"title":"Development rationale, access and market expectations"}],"counts":{"cited_sources":12,"claims_by_expression_type":{"comparison":4,"interpretation":7,"opinion":7,"primary_context":3,"restatement":7,"uncertainty":2},"claims_by_kind":{"interpretation":1,"protocol_statement":1,"source_observation":28},"clinician_statements":10,"evidence_units":14,"findings":7,"people_cited":9,"people_identity_verified":8,"people_total":9,"screened_sources":19,"verified_claims":30},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":3,"views":4},"has_counterview":true,"limitations":2,"links":{"context":0,"support":8},"ma_question":true,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Promising efficacy has not produced agreement on readiness for standard-of-care use"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":4,"views":1},"has_counterview":true,"limitations":3,"links":{"context":0,"support":8},"ma_question":true,"named_voices":6,"passages":7,"sources":7,"sources_by_kind":{"commentary":6,"publication":1}},"title":"Similar severe-event rates do not settle the tolerability question"},{"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":4,"passages":4,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Patient selection remains unresolved, with a distinct MET-testing alternative raised in the discussion"},{"id":"F4","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":2,"restated":1,"views":1},"has_counterview":false,"limitations":3,"links":{"context":1,"support":6},"ma_question":true,"named_voices":4,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"More active options have increased sequencing uncertainty rather than established a preferred option"},{"id":"F5","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":2},"has_counterview":false,"limitations":2,"links":{"context":1,"support":5},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Global applicability is an explicit concern with a stated population rationale"},{"id":"F6","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":1,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Intracranial activity is presented as promising but still requiring subgroup evaluation"},{"id":"F7","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Access and first-to-market expectations remain separate from clinical readiness"}],"medical_affairs_question":"What survival maturity, day-to-day toxicity, patient-selection evidence and access conditions would justify adoption in this post-TKI population?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Potential standard of care is not the same as current standard of care"},{"id":"section-2","level":2,"title":"Tolerability cannot be reduced to the severe-event rate"},{"id":"section-3","level":2,"title":"Selection involves both HER3-ADC prediction and resistance-directed alternatives"},{"id":"section-4","level":2,"title":"Expanding choices leave the treatment sequence unresolved"},{"id":"section-5","level":2,"title":"International applicability needs validation, not an assumption of failure"},{"id":"section-6","level":2,"title":"Intracranial optimism remains a subgroup question"},{"id":"section-7","level":2,"title":"Access and development expectations do not establish clinical readiness"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-free survival (PFS) assessed by BICR according to RECIST v1.1"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":3},{"id":"F5","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":7},{"id":"F5","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T07:40:20.185513Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T07:49:47Z","record_hash":"521fe81445728037285ce1974d688b21afea87516886abdb634cfae2919829ae","release_hash":"101c855017560d630f428eaa4650b7df5a80b9126a313f7a32e718b772d66901","report_id":"erudio-nct06671379","run_id":"1c03b77c-3f5e-4910-bdb6-6a00f7f70642","schema_version":"5.0","slug":"heron-lung01-06671379","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"HERON-Lung01 asks whether SHR-A2009 improves outcomes compared with platinum chemotherapy in advanced EGFR-mutated non-small cell lung cancer after EGFR-TKI failure. Clinicians in the sources reviewed for this edition differ on whether it is ready for standard-of-care use. Efficacy attracts enthusiasm, while tolerability remains under scrutiny in their commentary. Patient selection, treatment sequencing and applicability outside China remain open questions for positioning the treatment.","meta_description":"19 sources screened · 30 verified statements (10 from clinicians verified by NPI or staff page) from 12 sources · 7 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-e2f2d7ecee81b10ba55c"],"id":"F2","paraphrase":"An X-thread post asks about tolerability differences between ruzaltatug rezetecan and izabren.","source_channel":"x_thread","source_date":"2026-10-26","title":"Similar severe-event rates do not settle the tolerability question"},{"cited_claim_ids":["claim-3dc6c275b8104900aa6b"],"id":"F5","paraphrase":"An X-thread account addresses the question of applicability outside China in a discussion covering PANKU-Lung01 and HERON-Lung01.","source_channel":"x_thread","source_date":"2026-10-26","title":"Global applicability is an explicit concern with a stated population rationale"}]},"publication":{"approved_at":"2026-10-28T07:49:47Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-28T09:50:00Z","summary":"The trial is named HERON-Lung01, as its sources and the report name it (was SHR-A2009-301)"},{"affected_ids":[],"date":"2026-10-28T14:51:36Z","summary":"Corrected to match the delivered report: 12 sources cited (was 10); source breakdowns; the sample findings."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":19},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","15 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCP discussion. Comments without the trial identifier or recognizable names may be missing, and some available passages were not fully assessed for clinician views.","Several authors relay the same presentation or a discussion covering two trials. Separate posts and reposts should not be counted as independent clinical agreement.","OS remains immature in the commentary. The favorable trend was explicitly described as nonsignificant in a presentation account relayed by a speaker; an established survival benefit should not be inferred.","Cross-trial comparisons do not establish which ADC is more effective or better tolerated.","The CNS and detailed HER3 biomarker interpretations cover PANKU-Lung01 and HERON-Lung01 together; they cannot automatically be assigned to HERON-Lung01 alone.","The HERON-Lung01 lower-grade adverse-event wording does not define an exact grade range. The publication's treatment-related attribution of the death is possible, not definite.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","A full protocol and matching regulatory labels for the compared treatments were not included. A filing, potential launch date or first-to-market expectation does not establish approval, availability or prescribing conditions."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":0,"publication":1,"registry":1,"regulatory":0,"x_thread":10,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":10,"context":1,"methods":1},"count":12,"evidence_window":{"end":"2026-10-27","start":"2026-03-20"},"retrieval_snapshot":"2026-10-28T06:17:11.285341Z","timeline":[{"count":1,"week":"2026-W12"},{"count":9,"week":"2026-W44"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT06671379:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06671379:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42933457","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2034930608854765988:2a1624d8-23a0-4a72-948a-eaae5a7f5ea3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102774993209741626:280c0250-1de8-4c99-807a-cdbe7b893853","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114608928512508275:de889540-6666-43c5-be5f-0cfacea63acb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114636664505012617:b2555acc-db05-4a05-84b1-1f15fc93bf2b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114636891014508976:12ba3b96-b710-48a5-953f-934e6b3fce61","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114637106257478081:37560b99-c290-4aaf-8eac-b1ee7d5ddb32","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114637230845379058:ed29cd92-629b-4ba8-a6f7-a3b4c2641c5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114637778168479991:189441fa-c4d2-4fb8-916c-171c35eb037c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114637790046826635:0df10e17-b512-4acc-b7d5-5914a6a4f155","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114638273759072743:f8e0ff59-9fa9-4efa-a7a1-aabac6edf405","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114642027421811179:8a114b51-7880-4297-98e8-30861d4c9df4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114643141995229588:6986eece-4fc3-4cee-9d16-e36cdd15c924","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114644703983390769:6fa27495-472e-4837-a08a-b1c610c683d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114646320807841875:fa60c2d6-92e8-485a-a9df-0d8bf3e2e638","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114700845690261660:d5ee921a-5e55-4af2-9632-672c13fe8d1d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114747009748136062:1b3778bd-8e51-46eb-9648-3b9af8ef00b6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114838033493016642:fc20f46f-e172-47b9-b8e9-6c4fbb51f84e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114867222694739981:6e5250aa-e77c-4419-a086-c3e86ccc4e2e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115091675878179009:a7b5bd73-54f2-429d-8641-bb2abfe95991","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":19,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":19},"count":19,"evidence_window":{"end":"2026-10-27","start":"2026-03-20"},"retrieval_snapshot":"2026-10-28T06:17:11.285341Z","timeline":[{"count":1,"week":"2026-W12"},{"count":1,"week":"2026-W39"},{"count":17,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: shr-a2009 monotherapy","status":"unmapped"},{"reason":"Unmapped registry intervention: platinum-based dual-agent chemotherapy","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"HERON-Lung01","aliases":["HERON-Lung01","A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy"],"brief_title":"A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":498,"type":"ACTUAL"},"interventions":[{"name":"SHR-A2009 monotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"platinum-based dual-agent chemotherapy","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06671379","official_title":"A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Progression-free survival (PFS) assessed by BICR according to RECIST v1.1","timeFrame":"Up to approximately 32 months"}],"registry_last_updated":"2026-03-19","registry_url":"https://clinicaltrials.gov/study/NCT06671379","short_name":"HERON-Lung01","short_name_basis":"canonical_name","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","start_date":{"date":"2024-11-29","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"SHR-A2009-301","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}